SG Americas Securities’s Akcea Therapeutics Inc AKCA Stock Holding History

SG Americas Securities’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-71,598	Closed	-$1.3M	–	3561
2020 Q3	$1.3M	Buy	71,598 +33,642	+89%	+$477K	0.01%	1034
2020 Q2	$520K	Buy	37,956 +29,984	+376%	+$463K	﹤0.01%	2062
2020 Q1	$114K	Buy	+7,972	New	+$131K	﹤0.01%	2906
2019 Q2	–	Sell	-5,677	Closed	-$161K	–	3593
2019 Q1	$161K	Buy	5,677 +1,831	+48%	+$53.3K	﹤0.01%	2725
2018 Q4	$116K	Buy	+3,846	New	+$108K	﹤0.01%	2655
2018 Q1	–	Sell	-6,951	Closed	-$121K	–	3677
2017 Q4	$121K	Buy	+6,951	New	+$136K	﹤0.01%	2756

SG Americas Securities's AKCA Position: Q4 2020 in Review

SG Americas Securities sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 71,598 shares — an estimated $1.3M sold.

SG Americas Securities first reported a position in AKCA in Q4 2017 and held it in 6 quarters. The position peaked at $1.3M in Q3 2020. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

SG Americas Securities reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
SG Americas Securities sold 71,598 Akcea Therapeutics Inc shares in Q4 2020, an estimated $1.3M.
SG Americas Securities first reported a position in Akcea Therapeutics Inc in Q4 2017 and held it in 6 quarters.
SG Americas Securities's Akcea Therapeutics Inc position peaked at $1.3M in Q3 2020.
0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on SG Americas Securities's 13F filing for Q4 2020, filed 4 Feb 2021.